Login to Your Account

AMD, retinal diseases market hardly bearish: $34M Kodiak series B

By Randy Osborne
Staff Writer

Tuesday, January 12, 2016

Even with a lineup of FDA-cleared therapies available for the condition, age-related macular degeneration (AMD) continues to draw interest, as drug developers work to invent still more efficacious and longer-lasting treatments for the blindness-causing scourge of the elderly.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription